Sanofi-aventis Announces the Creation of the "Sanofi Espoir" Corporate Foundation

Sanofi-aventisSanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced the creation of the Sanofi Espoir Corporate Foundation, dedicated to implementing health and solidarity programs worldwide.

For more than 20 years, the commitment of the sanofi-aventis Group and its employees has been exemplified in wide-ranging community actions that aim to help and provide emergency humanitarian aid, enable better access to healthcare and combat chronic illness in developing countries. Constructed with the support and competencies of partners involved in the communities, these programs are part of a long-term development approach, with the objective of providing long-term support for the most vulnerable populations.

Aiming to capitalize on existing initiatives and develop new programs, the sanofi-aventis Group decided to create this Corporate Foundation, Sanofi Espoir, which will be chaired by Jean-François Dehecq. Hence, sanofi-aventis wants, through innovative measures, to pursue its goal of helping provide healthcare access to those patients who need it most.

"We are very pleased that Jean-François Dehecq will chair the Sanofi Espoir Foundation as it will continues to support the company's values and will allow us to put into practice important measures focusing on health issues in our civilization today," declared Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis. "Health and Solidarity correspond to massive needs in terms of prevention, access and education. The Sanofi Espoir Corporate Foundation will find its strength in the engagement of all our employees."

About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Most Popular Now

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...

Addressing social and cultural drivers of type 2 d…

New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and ...

Evidence mounts linking aspirin to lower risk of o…

Taking a low-dose aspirin daily may help women lower their risk of developing ovarian cancer. A new study co-led by Moffitt Cancer Center found that women who reported ta...